Sirius Therapeutics Appoints Dr. Patrick Yue as Chief Medical Officer to Advance Clinical Development of siRNA Pipeline

(Shanghai and San Diego, July 8, 2024) Sirius Therapeutics announced the appointment of Dr. Patrick Yue as the company's Chief Medical Officer.

Dr. Peichuan Yu, Chief Medical Officer of Sirius Therapeutics

Image Source:Sirius TherapeuticsOfficial WeChat

Dr. Qunsheng Ji, CEO of Sirius Therapeutics, stated:

Patrick is a seasoned talent in the pharmaceutical industry. He has extensive and successful experience in leading the clinical development of innovative drugs, including in the field of anticoagulation therapy, and has played a core role in the development and market approval of multiple products in the United States and globally. The marketed products he has led the development of include ANDEXXA® (Factor Xa [Recombinant]) and voxelotor (Voxelotor). Currently, Sirius Therapeutics' siRNA project is about to enter the mid-stage clinical development phase, and other early-stage projects will gradually move into clinical development. Patrick’s addition comes at just the right time.

Dr. Yu has extensive leadership experience in the clinical development of innovative therapies. Prior to joining Sirius Therapeutics, he served as Senior Vice President of Clinical Development at Centessa Pharmaceuticals, where he led the development of SerpinPC in Phase 2b/3 clinical trials and ORX-750 in Phase 1 clinical trials. SerpinPC is an inhibitor of activated protein C for the treatment of hemophilia, while ORX-750 is an OX2R agonist for the treatment of narcolepsy. Before joining Centessa, Dr. Yu held the roles of Head of Clinical Science and Vice President at Global Blood Therapeutics (GBT), which was acquired by Pfizer in 2022. During his tenure, he was responsible for the clinical development of four products, including the EU market approval of voxelotor (OXBRYTA®) for the treatment of sickle cell disease and its pediatric indication expansion in the United States. Previously, he held clinical development management positions at Portola Pharmaceuticals, Alexion Pharmaceuticals, and Gilead Sciences in the United States.

Before joining the pharmaceutical industry, Dr. Yu completed his clinical internship and residency training at Beth Israel Deaconess Medical Center, Harvard University, in the United States. He then received specialized training in cardiovascular clinical medicine at Stanford University School of Medicine. Dr. Yu holds a Bachelor of Science degree in Biology and Chemistry from the California Institute of Technology and a Doctor of Medicine degree from Washington University School of Medicine.

About Sirius Therapeutics

Sirius Therapeutics is an innovative biotechnology company dedicated to advancing human health and well-being. Focused on the development of next-generation nucleic acid therapies for cardiovascular diseases, the company aims to become a leader in transforming the prevention and treatment of chronic diseases. Its current pipeline includes SRSD107, which is in clinical development for thromboembolic disorders, and SRDS101, aimed at treating dyslipidemia.

Founded in 2021 and incubated by an internationally outstanding management team and globally renowned healthcare investment institutions, Sirius Therapeutics has established a layout with the United States as the source of innovative discovery center and China as the global translational medicine center. To date, the company has raised nearly 100 million US dollars from OrbiMed, Hongyuan Capital, Hanco Capital, Prosper Global Investment Fund, and the leadership team. For more information, please visit www.siriusrna.com.

Editor: Baiji

Disclaimer: This article is a reprint from Pharmacist Network. The images and text are the original property of the author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding the content, copyright, or other aspects, please leave a message on this platform, and we will address it promptly.